A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease

NCT ID: NCT05403827

Last Updated: 2025-01-14

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

644 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-03

Study Completion Date

2023-12-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the efficacy and safety of K-161 ophthalmic solution for the treatment of moderate to severe dry eye disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

K-161

K-161 Ophthalmic Solution

Group Type EXPERIMENTAL

K-161

Intervention Type DRUG

K-161 Ophthalmic Solution

Placebo

Vehicle Solution

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Vehicle Solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

K-161

K-161 Ophthalmic Solution

Intervention Type DRUG

Placebo

Vehicle Solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be at least 18 years of age at the time of Informed Consent
* Have a reported history of dry eye disease in both eyes and a history of eye drop use for dry eye symptom

Exclusion Criteria

* Have any clinically significant ocular condition
* Have a history of corneal refractive surgery and/or any other ocular surgical procedure within 12 months
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kowa Research Institute, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andrey E. Belous, MD, PhD

Role: STUDY_CHAIR

Kowa Pharma Development Co.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The University of Alabama at Birmingham School of Optometry, Clinical Eye Research Center

Birmingham, Alabama, United States

Site Status

Trinity Research Group

Dothan, Alabama, United States

Site Status

Cornea and Cataract Consultants of Arizona

Phoenix, Arizona, United States

Site Status

Citrus Valley Eyecare / Premiere Practice Management, LLC

Covina, California, United States

Site Status

Orange County Ophthalmology Medical Group

Garden Grove, California, United States

Site Status

Global Research Management

Glendale, California, United States

Site Status

Inland Eye Specialists

Hemet, California, United States

Site Status

United Medical Research Institute

Inglewood, California, United States

Site Status

Premiere Practice Management, LLC

Los Angeles, California, United States

Site Status

North Valley Eye Medical Group, Inc

Mission Hills, California, United States

Site Status

LoBue Laser and Eye Medical Center

Murrieta, California, United States

Site Status

Eye Research Foundation, Inc.

Newport Beach, California, United States

Site Status

Pendleton Eye Center

Oceanside, California, United States

Site Status

Martel Eye Medical Group

Rancho Cordova, California, United States

Site Status

Sierra Clinical Trial Research Organization

Santa Ana, California, United States

Site Status

Premiere Practice Management, LLC

Torrance, California, United States

Site Status

Wolstan and Goldberg Eye Associates

Torrance, California, United States

Site Status

Vision Institute

Colorado Springs, Colorado, United States

Site Status

Corneal Consultants of Colorado dba Colorado Eye Consultants

Littleton, Colorado, United States

Site Status

Segal Drug Trials

Delray Beach, Florida, United States

Site Status

Bowden Eye & Associates

Jacksonville, Florida, United States

Site Status

Shettle Eye Research, Inc.

Largo, Florida, United States

Site Status

International Research Center

Tampa, Florida, United States

Site Status

Dixophthal, PC.

Albany, Georgia, United States

Site Status

Edwin Yoshio Endo, OD & Associates & Interns

‘Aiea, Hawaii, United States

Site Status

Chicago Cornea Consultants

Hoffman Estates, Illinois, United States

Site Status

Jones Eye Clinic and Surgery Center

Sioux City, Iowa, United States

Site Status

Seidenberg Protzko Eye Associates

Havre de Grace, Maryland, United States

Site Status

Midwest Vision Research Foundation at Pepose Vision Institute

Chesterfield, Missouri, United States

Site Status

Tauber Eye Center

Kansas City, Missouri, United States

Site Status

Tekwani Vision Center

St Louis, Missouri, United States

Site Status

Ophthalmology Associates

St Louis, Missouri, United States

Site Status

Comprehensive Eye Care, Ltd.

Washington, Missouri, United States

Site Status

Wellish Vision Institute

Las Vegas, Nevada, United States

Site Status

Asheville Eye Associates

Asheville, North Carolina, United States

Site Status

Oculus Research

Garner, North Carolina, United States

Site Status

Wake Forest Health Network, LLC

High Point, North Carolina, United States

Site Status

Insight Research Clinic, LLC dba EyeCare Professionals

Powell, Ohio, United States

Site Status

Conestoga Eye PC

Lancaster, Pennsylvania, United States

Site Status

Associates in Ophthalmology Ltd

West Mifflin, Pennsylvania, United States

Site Status

West Bay Eye Associates

Warwick, Rhode Island, United States

Site Status

Total Eye Care, PA

Memphis, Tennessee, United States

Site Status

Advancing Vision Research

Smyrna, Tennessee, United States

Site Status

Keystone Research

Austin, Texas, United States

Site Status

Hill Country Eye Center

Cedar Park, Texas, United States

Site Status

Southwest Eye Institute

El Paso, Texas, United States

Site Status

Lake Travis Eye and Laser Center/Revolution Research

Lakeway, Texas, United States

Site Status

R and R Eye Research, LLC

San Antonio, Texas, United States

Site Status

DCT-Shah Research, LLC dba Discovery Clinical Trials

San Antonio, Texas, United States

Site Status

Northern Virginia Ophthalmology Associates

Falls Church, Virginia, United States

Site Status

Virginia Eye Consultants, Inc.

Norfolk, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol: Initial

View Document

Document Type: Study Protocol: Amendment 1

View Document

Document Type: Study Protocol: Amendment 2

View Document

Document Type: Statistical Analysis Plan: Ver 1.0

View Document

Document Type: Statistical Analysis Plan: ver 1.0 Addendum

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

K-161-3.01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.